在临床实践中实施和优化前列腺癌患者的普遍胚系基因检测
本文倡导在前列腺癌患者中实施普遍胚系基因检测(UGGT),并给出实践建议。指南虽已进展,但检测使用率低且不一致,受可及性、费用和指南依从性差异等障碍影响。PROCLAIM试验(Shore等,2023)显示按NCCN指南近半数致病性变异患者被漏检,尤其影响非白人患者和家族史数据不完整者。2024年3月专家会议形成整合UGGT于肿瘤和泌尿外科实践的建议。
要点
- PROCLAIM试验显示按NCCN指南近半数致病性变异患者被漏检,尤其影响非白人患者和家族史不完整者。
- 2024年3月前列腺癌专家会议形成将UGGT整合于肿瘤和泌尿外科实践的建议。
- 实施UGGT需关注基因面板选择、意义未明变异报告与管理、遗传学随访及检测报告整合电子病历。
核心结论
- 为最大化UGGT获益并降低潜在风险,必须解决实施细节,包括仔细选择基因面板、意义未明变异的报告与管理、适当的遗传学随访,以及将检测报告无缝整合到电子病历中供患者和提供者访问。
研究设计与样本
- 2024年3月,前列腺癌专家召开会议讨论UGGT实施策略,会议结果形成本文所述建议。
主要发现
- PROCLAIM试验(Shore等,2023)显示,按美国国家综合癌症网络(NCCN)指南,近半数携带致病性变异的患者被漏检,尤其影响非白人患者和家族史数据不完整者。
- 种族和社会经济差异进一步阻碍了检测可及性和变异解读准确性。
- 指南虽已进展,但由于可及性、费用和指南依从性差异等障碍,胚系基因检测的使用仍然有限且不一致。
关键数值与推荐
- 原文未报告具体推荐条款。
临床怎么用
- 原文建议将UGGT整合到肿瘤和泌尿外科实践中,并关注基因面板选择、意义未明变异报告与管理、遗传学随访及检测报告整合电子病历。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To advocate for universal germline genetic testing (UGGT) in prostate cancer and provide practical recommendations for its implementation. METHODS: Although guidelines for germline genetic testing in prostate cancer have progressed, usage remains limited and inconsistent due to barriers including access, cost, and variable guideline adherence. These issues prevent some patients with germline pathogenic/likely pathogenic variants from benefiting from risk assessment, precision therapies (eg, PARP inhibitors, PD-1 inhibitors), and potential clinical trials. Despite these benefits, studies indicate that germline genetic testing use remains low, especially in prostate cancer care. The PROCLAIM trial (Shore et al, 2023) highlighted that nearly half of patients with pathogenic variants are missed under National Comprehensive Cancer Network guidelines, particularly impacting non-white patients and those with incomplete family history data. Additional racial and socioeconomic disparities further hinder access and variant interpretation accuracy. Given these challenges, UGGT for all prostate cancer patients has been proposed to improve care equity and decision-making. In March 2024, prostate cancer experts convened to discuss strategies for UGGT implementation. RESULTS: The outcome of that meeting includes recommendations for integrating UGGT into oncology and urology practices and have been outlined in this paper. CONCLUSION: To maximize the benefits while mitigating the potential risks of UGGT, it is essential to address implementation details, including careful gene panel selection, variants of uncertain significance reporting and management, appropriate genetics follow-up, and seamless integration of test reports into electronic medical records for accessibility by patients and providers.
引用
- Shore N, Armstrong AJ, Barata P, et al. Implementing and Optimizing Universal Germline Genetic Testing for Patients With Prostate Cancer in Clinical Practice. Urology. 2025. PMID: 39909130. doi:10.1016/j.urology.2025.01.070
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。